04/04/2025

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

04/04/2025

Apr 4, 2025, 20:41 | Blog
Michael Sapienza: Colorectal Cancer Alliance is hiring a VP of Data Intelligence and Technology
Michael Sapienza, Chief Executive Officer of the Colorectal Cancer Alliance, shared a post on LinkedIn:…
Apr 4, 2025, 20:29 | Science
Gaëlle Saint-Hilary: Benefit-risk assessment of ivosidenib vs. placebo in mIDH1 cholangiocarcinoma
Gaëlle Saint-Hilary, CEO, Statistical methodologist at Saryga, shared a post on LinkedIn about a paper…
Apr 4, 2025, 20:12 | Blog
David Planchard: A pleasure to discuss diagnostic and therapeutic advances in EGFR lung patients in Cannes
David Planchard, Thoracic Oncologist, Professor at University Paris Saclay and Head of Thoracic Cancer Group…
Apr 4, 2025, 19:52 | Science
Paolo Bossi: Immunotherapy plus cetuximab in advanced/metastatic cutaneous squamous cell carcinoma
Paolo Bossi, Head of the Head and Neck Medical Oncology Unit and Associate Professor of…
Apr 4, 2025, 19:34 | Blog
Matthew Kurian: The barriers to AI adoption in oncology
Matthew Kurian, Physician at St. Elizabeth Healthcare and Assistant Professor of Medicine at the University…
Apr 4, 2025, 19:19 | Blog
Michaela Cada: Proud to be part of the SickKids family for 20 years
Michaela Cada, Chief Reinvention Officer of Project Horizon and Pediatric Hematologist/Oncologist at The Hospital for…
Apr 4, 2025, 19:05 | Blog
Laurence Albiges: Day 1 of ESMO Preceptorship in metastatic urothelial RCC cancer
Laurence Albiges, Chair of Medical Oncology Department at Gustave Roussy, shared a post on X:…
Apr 4, 2025, 18:55 | Blog
The invisible killer in your lungs - Pink Hearts Cancer Support Foundation
Pink Hearts Cancer Support Foundation shared on X: "The invisible killer in your lungs! Every…
Apr 4, 2025, 18:54 | Blog
Yelak Biru: How pharma medical affairs and innovation teams can learn from Myelo’s AI journey
Yelak Biru, President and Chief Executive Officer at International Myeloma Foundation, shared a post on…
Apr 4, 2025, 18:36 | Insight
Luis Lara-Mejía: Neoadjuvant aumolertinib converted 45.1% of unresectable stage III EGFRm NSCLC to resectable status
Luis Lara-Mejía, Medical Oncologist Specialized in Thoracic Neoplasms at National Institute of Cancerology, shared on…
All: 94 Posts: 1 - 10
Special Coverage